PhaseBio Pharmaceuticals Inc. (PHAS)
$0.04
$0.00
(5.26%)
As on 04-Jan-2023 09:30EDT
Market cap
$4 Mln
Revenue (TTM)
$-10 Mln
P/E Ratio
--
P/B Ratio
26.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-103 Mln
-
ROE
-30.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
49,858,100
6 Years Aggregate
CFO
$-181.97 Mln
EBITDA
$-170.53 Mln
Net Profit
$-181.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PhaseBio Pharmaceuticals (PHAS)
| 32.9 | -19.2 | -77.8 | -98.5 | -80.4 | -- | -- |
|
BSE Sensex*
| -10.0 | 1.0 | 2.2 | -7.5 | 6.4 | 7.7 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|
|
PhaseBio Pharmaceuticals (PHAS)
| -98.8 | -22.3 | -45.0 | 97.7 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout PhaseBio Pharmaceuticals (PHAS)
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the... antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Pres, CEO & Director
Mr. Jonathan P. Mow MBA
-
Pres, CEO & Director
Mr. Jonathan P. Mow MBA
-
Headquarters
Malvern, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for PhaseBio Pharmaceuticals (PHAS)
What is the current share price of PhaseBio Pharmaceuticals Inc (PHAS) Today?
The share price of PhaseBio Pharmaceuticals Inc (PHAS) is $0.04 (NASDAQ) as of 04-Jan-2023 09:30 EDT. PhaseBio Pharmaceuticals Inc (PHAS) has given a return of -80.38% in the last 3 years.
What is the current PB & PE ratio of PhaseBio Pharmaceuticals Inc (PHAS)?
Since, TTM earnings of PhaseBio Pharmaceuticals Inc (PHAS) is negative, P/E ratio is not available.
The P/B ratio of PhaseBio Pharmaceuticals Inc (PHAS) is 26.18 times as on 04-Jan-2023, a 509 premium to its peers’ median range of 4.30 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of PhaseBio Pharmaceuticals Inc (PHAS)?
The 52-week high and low of PhaseBio Pharmaceuticals Inc (PHAS) are Rs -- and Rs -- as of 24-Jun-2026.
What is the market cap of PhaseBio Pharmaceuticals Inc (PHAS)?
PhaseBio Pharmaceuticals Inc (PHAS) has a market capitalisation of $ 4 Mln as on 04-Jan-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in PhaseBio Pharmaceuticals Inc (PHAS)?
Before investing in PhaseBio Pharmaceuticals Inc (PHAS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.